APCCC 2024: Management of Patients with mHSPC and Early Progression on Combination Therapy
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), mHSPC and early progression on combination therapy, androgen deprivation therapy (ADT), abiraterone, enzalutamide, apalutamide, darolutamide, androgen deprivation therapy plus abiraterone, androgen deprivation therapy plus enzalutamide, androgen deprivation therapy plus apalutamide, androgen deprivation therapy plus darolutamide, ENZAMET trial, PSMAfore trial, p53, RB1, PTEN, oligometastatic prostate cancer, VISION trial, LuPSMA, cabazitaxel, LuPSMA versus cabazitaxel, PROfound trial, TAX-327 trial, mitoxantrone, olaparib, TROPIC trial, CARD trial.